Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2500${count})

  • Research Grant, 2020
    Assessing Target Engagement for Terazosin

    Study Rationale:    
    Patients with Parkinson’s disease (PD) do not produce enough of a compound called ATP. If a person does not make enough ATP, the cells in the body can die. This is very important...

  • Research Grant, 2020
    Safety and Tolerability of NLX-112 in People with Parkinson’s

    Study Rationale:
    Motor symptoms of Parkinson’s disease are caused by a lack of brain neurons that carry a neurotransmitter called dopamine, and are commonly treated with levodopa. However, after...

  • Biosample Use Program, 2020
    Mass Spectrometric Analysis of Glucocerebrosidase Protein Levels and Spinal Fluid in People with Parkinson’s

    Study Rationale:
    Mutations in the glucocerebrosidase (GBA) gene are among the most important risk factors for developing Parkinson´s disease. GBA activity is reduced in cerebrospinal fluid (CSF) of...

  • Priority Biology, 2021
    LRRK2 Regulation of Melanoma Progression

    Study Rationale:
    People with Parkinson's disease (PD) are more likely to develop melanoma, and people with melanoma are more likely to develop PD than the general population. Additionally, melanoma...

  • Research Grant, 2020
    Alpha-synuclein Toxicity in LRRK2 Knock-in Models and Rescue by LRRK2 Silencing

    Study Rationale:
    Gene mutations that alter the function of the LRRK2 protein are known to increase the risk of developing Parkinson’s disease (PD). One of the pathological hallmarks of PD is the...

  • Research Grant, 2020
    Evaluation of ANAVEX2-73 (blarcamesine) in Participants with Parkinson’s Disease

    Study Rationale:    
    We are testing ANAVEX2-73 (also known as blarcamesine), which previous research has shown helps improve behaviors as well as normalizes biochemical changes in a Parkinson’s...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.